Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | GBA1 | P04062 | 2/20 | 0.51 |
| ▸ | LTA4H | P09960 | 2/20 | 0.51 |
| ▸ | CCR3 | P51677 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13343789 | 0.87 | ACHE (0.55) | ALDH1A1HRH3LMNAACHESIGMAR1 | |
| SCHEMBL27883986 | 0.84 | ACHE (0.55) | HRH3ACHESIGMAR1LTA4HCCR3 | |
| SCHEMBL3142114 | 0.83 | SIGMAR1 (0.53) | HRH3ACHESIGMAR1LTA4HCCR3 | |
| SCHEMBL4592063 | 0.83 | ALDH1A1 (0.54) | ALDH1A1HRH3ACHESIGMAR1LTA4H | |
| SCHEMBL1505926 | 0.83 | — | — | |
| SCHEMBL3156587 | 0.83 | LMNA (0.59) | ALDH1A1HRH3LMNAACHESIGMAR1 | |
| SCHEMBL12504038 | 0.83 | HRH3 (0.56) | ALDH1A1HRH3LMNAACHELTA4H | |
| SCHEMBL349053 | 0.82 | CCR3 (0.71) | ALDH1A1ACHESIGMAR1LTA4HCCR3 | |
| SCHEMBL3158673 | 0.82 | ALDH1A1 (0.61) | ALDH1A1HRH3LMNAACHESIGMAR1 | |
| SCHEMBL20804048 | 0.82 | HRH3 (0.59) | ALDH1A1HRH3LMNAACHELTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579356-B2 | Thia-tetraazaacenaphthylene kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-25 | — | — | US | claimed |
| US-7427625-B2 | Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-09-23 | — | — | US | claimed |
| US-20070265264-A1 | 5-(3-chloro-4-fluoro-phenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,6,8-tetraaza-acenaphthylene-2-carboxylic acid (3,4-dimethoxy-phenyl)-amide | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-15 | — | — | US | claimed |
| US-20070225309-A1 | SUBSTITUTED THIATRIAZAACENAPHTHYLENE-6-CARBONITRILE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-09-27 | — | — | US | claimed |
| WO-2007092879-A2 | SUBSTITUTED THIATRIAZAACENAPHTHYLENE-6-CARBONITRILE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-16 | — | — | WO | claimed |
| WO-2023080732-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | 주식회사 유빅스테라퓨틱스 | 2023-05-11 | — | — | WO | disclosed |
| EP-3823969-A1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2021-05-26 | — | — | EP | disclosed |
| WO-2020016129-A1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2020-01-23 | — | — | WO | disclosed |
| CN-107001318-A | N- (hetero) aryl-substituted heterocyclic derivatives useful for the treatment of diseases or disorders associated with the central nervous system | 克罗诺斯治疗有限公司 | 2017-08-01 | — | — | CN | disclosed |
| EP-3194385-A1 | N-(HETERO)ARYL-SUBSTITUTED HETEROYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES OR CONDITIONS RELATED TO THE CENTRAL NERVOUS SYSTEM | Chronos Therapeutics Limited (GB) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016042453-A1 | N-(HETERO)ARYL-SUBSTITUTED HETEROYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES OR CONDITIONS RELATED TO THE CENTRAL NERVOUS SYSTEM | SHIRE INTERNATIONAL GMBH (CH) | 2016-03-24 | — | — | WO | disclosed |
| EP-2166846-A1 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20080300264-A1 | SUBSTITUTED THIATRIAZAACENAPHTHYLENE-6-CARBONITRILE KINASE INHIBITORS | CONNOLLY PETER J | 2008-12-04 | — | — | US | disclosed |
| EP-1994020-A2 | SUBSTITUTED QUINOLONES III | AiCuris GmbH & Co. KG (DE) | 2008-11-26 | — | — | EP | disclosed |
| US-7427625-B2 | Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-09-23 | — | — | US | disclosed |
| US-20070265264-A1 | 5-(3-chloro-4-fluoro-phenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,6,8-tetraaza-acenaphthylene-2-carboxylic acid (3,4-dimethoxy-phenyl)-amide | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-15 | — | — | US | disclosed |
| US-20070225309-A1 | SUBSTITUTED THIATRIAZAACENAPHTHYLENE-6-CARBONITRILE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-09-27 | — | — | US | disclosed |
| WO-2007092879-A2 | SUBSTITUTED THIATRIAZAACENAPHTHYLENE-6-CARBONITRILE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007090579-A2 | SUBSTITUTED QUINOLONES III | AICURIS GMBH & CO. KG (DE) | 2007-08-16 | — | — | WO | disclosed |
| WO-2006118749-A1 | THIA-TETRAAZAACENAPHTHYLENE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225309-A1 | SUBSTITUTED THIATRIAZAACENAPHTHYLENE-6-CARBONITRILE KINASE INHIBITORS | MAP3K11, MAP3K6, MAP4K2 | ALDH1A1 2543/4885HRH3 2500/4885LMNA 2852/4885 |
| US-20070265264-A1 | 5-(3-chloro-4-fluoro-phenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,6,8-tetraaza-acenaphthylene-2-carboxylic acid (3,4-dimethoxy-phenyl)-amide | ADK, MAP3K9, MAP4K5 | ALDH1A1 924/4885HRH3 1681/4885LMNA 3244/4885 |
| US-20080300264-A1 | SUBSTITUTED THIATRIAZAACENAPHTHYLENE-6-CARBONITRILE KINASE INHIBITORS | MAP3K11, MAP3K6, MAP4K2 | ALDH1A1 2543/4885HRH3 2500/4885LMNA 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.